arrow
Back
S

Syed A. Hussain

University of Sheffield and Sheffield Teaching Hospitals

49H-index
425Paper Count
1.4WCitation Count
Published Papers 125
Publication Date
A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer
err2026-04-27
err0
errOAAI
errSyed A. Hussain; Amarnath Challapalli; Simran Gill; Michael Hubank; Hannah Markham; Philippe Tanière; Simon Wyatt; Robert Jones
errShare
errSave
Treatment Sequencing in Advanced Urothelial Cancer
errDrugs
IF14.4
err2026-01-19
err0
PREAI
errIrbaz B. Riaz; Muhammad Abdullah Humayun; Ali Raza Khaki; Syed A. Hussain
errShare
errSave
errShare
errSave
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
err2025-10-01
err0
errOAAI
errGrande, Enrique; Bellmunt, Joaquim; Hussain, Syed A.; Al Mansour, Mubarak M.; Bamias, Aristotle; Barthelemy, Philippe; Benjamin, David J.; Blais, Normand; Bourlon, Maria T.; Castellano, Daniel; Danchaivijitr, Pongwut; Fernandez Lazzaro, Mauricio; Giannatempo, Patrizia; Guerrero-Ramos, Felix; Iacovelli, Roberto; Ivanyi, Philipp; Jung, Eun Hee; Kanesvaran, Ravindran; Manneh, Ray; Marinho, Joana C.; Matsubara, Nobuaki; Merseburger, Axel S.; Mukherji, Deborah; Park, Chandler H.; Tran, Ben; da Trindade, Karine Martins; Urun, Yuksel; Kamat, Ashish M.; Birtle, Alison J.
errShare
errSave
UK multidisciplinary recommendations on use of combination first-line enfortumab vedotindel and pembrolizumab in advanced urothelial carcinoma
err2025-10-01
err0
PREAI
errHussain, Syed; Carr, Aisling; Crabb, Simon John; Dodhia, Vikash; Fearfield, Louise; Malik, Jahangeer Mahmood; Lapuente, Maria; Lau, Davina; Petruskin, Harry; Sarwar, Naveed; Smith, Nicola Jane; Stevenson, Robert; Jones, Robert
errShare
errSave
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
err2025-04-17
err0
errOAAI
errBernadett E. Szabados; Félix Guerrero-Ramos; Enrique Grande; Petros Grivas; Viktor Grünwald; Marta Carpintero Miguel; Syed A. Hussain; Girish S. Kulkarni; Ana Lisa Wilson; Neal D. Shore; Srikala S. Sridhar; Mary Hoyt; Samantha Strumeier; Jennifer Sutton; Julia Brinkmann; Rosemary E. Teresi; Tilman Todenhöfer
errShare
errSave
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians
err2025-03-01
err0
errOAAI
errGrande, Enrique; Hussain, Syed A.; Barthelemy, Philippe; Kanesvaran, Ravindran; Giannatempo, Patrizia; Benjamin, David J.; Hoffman, Jason; Birtle, Alison
errShare
errSave
A UNIQUE CASE OF DIFFUSE ALVEOLAR HEMORRHAGE RELATED TO HYDRALAZINE
err2025-01-30
err0
PREAI
errBrandel, Maria; Smith, Christy; Hussain, Syed; Gardner, Katie
errShare
errSave
Nano-protected form of rosemary essential oil has a positive influence on blood biochemistry parameters, haematological indices, immune-antioxidant status, intestinal microbiota and histomorphology of meat-type chickens
err2024-12-01
err2
errOAAI
errAdil, Sheikh; Banday, Muhammad T.; Wani, Manzoor A.; Hussain, Syed A.; Shah, Showkat; Sheikh, Islam D.; Shafi, Majid; Khan, Azmat A.; Kashoo, Zahid A.; Pattoo, Roof A.; Swelum, Ayman A.
errShare
errSave
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial
err2024-09-26
err0
errOAAI
errConroy, Samantha; Jubber, Ibrahim; Noon, Aidan P.; Rosario, Derek J.; Griffin, Jon; Morgan, Susan; Hubbard, Rachel; Kennish, Steve; Mitchell, Stephen; Venugopal, Suresh; Linton, Kate; Rajasundaram, Ramanan; Hussain, Syed A.; Catto, James W. F.
errShare
errSave
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial
err2024-03-01
err3
errOAAI
errSmith, Tim A. D.; West, Catharine M. L.; Joseph, Nuradh; Lane, Brian; Irlam-Jones, Joely; More, Elisabet; Mistry, Hitesh; Reeves, Kimberley J.; Song, Yee Pei; Reardon, Mark; Hoskin, PeterJ.; Hussain, Syed A.; Denley, Helen; Hall, Emma; Porta, Nuria; Huddart, Robert A.; James, Nick D.; Choudhury, Ananya
errShare
errSave
Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial
err2024-02-01
err9
errOAAI
errGriffin, Jon; Down, Jenny; Quayle, Lewis A.; Heath, Paul R.; Gibb, Ewan A.; Davicioni, Elai; Liu, Yang; Zhao, Xin; Swain, Jayne; Wang, Dennis; Hussain, Syed; Crabb, Simon; Catto, James W. F.
errShare
errSave
Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective
err2024-01-08
err10
errOAAI
errJones, Robert J.; Crabb, Simon J.; Linch, Mark; Birtle, Alison J.; McGrane, John; Enting, Deborah; Stevenson, Robert; Liu, Kin; Kularatne, Bihani; Hussain, Syed A.
errShare
errSave
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
err2024-01-01
err21
errOAAI
errCatto, J. W. F.; Tran, B.; Roupret, M.; Gschwend, J. E.; Loriot, Y.; Nishiyama, H.; Redorta, J. P.; Daneshmand, S.; Hussain, S. A.; Cutuli, H. J.; Procopio, G.; Guadalupi, V.; Vasdev, N.; Naini, V.; Crow, L.; Triantos, S.; Baig, M.; Steinberg, G.
errShare
errSave
Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection
err2023-11-01
err19
errOAAI
errMeeks, Joshua J.; Black, Peter C.; Galsky, Matthew; Grivas, Petros; Hahn, Noah M.; Hussain, Syed A.; Milowsky, Matthew I.; Steinberg, Gary D.; Svatek, Robert S.; Rosenberg, Jonathan E.
errShare
errSave
THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non emuscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guerin (BCG) treatment
err2023-10-01
err0
PREAI
errCatto, J. W. F.; Tran, B.; Roupret, M.; Gschwend, J. E.; Loriot, Y.; Nishiyama, H.; Palou, J.; Daneshmand, S.; Hussain, S. A.; Cutuli, H. J.; Procopio, G.; Guadalupi, V.; Vasdev, N.; Naini, V.; Crow, L.; Triantos, S.; Baig, M.; Steinberg, G. D.
errShare
errSave
DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints
err2023-10-01
err1
errOAAI
errJackson-Spence, F.; Pinto Marin, A.; Puente, J.; Molina-Cerrillo, J.; Hussain, S. A.; Ackerman, C.; Bonsu, N.; Kelly, J.; Loriot, Y.; Powles, T. B.; Grande Pulido, E.
errShare
errSave
phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
err2023-10-01
err3
PREAI
errSzabados, B. E.; Nogueron Martinez, E.; Alvarez Marquez, F. J.; Castellano Gauna, D. E.; Rodriguez-Vida, A.; Garcias de Espana, M. C.; Hussain, S. A.; Alvarez Fernandez, C.; Linch, M.; Bonfill Abella, T.; Goupil, M. Gross; Kelly, J.; Jones, R. J.; Crabb, S.; Beltran, L.; Garonce-Hediger, R.; Rakebrandt, N. J.; Georgescu, R.; Ackerman, C.; Powles, T. B.
errShare
errSave
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer
err2023-08-03
err3
errOAAI
errMacaulay, Valentine M.; Lord, Simon; Hussain, Syed; Maroto, Jose Pablo; Jones, Robert Hugh; Climent, Miguel Angel; Cook, Natalie; Lin, Chia-Chi; Wang, Shian-Shiang; Bianchini, Diletta; Bailey, Mark; Schlieker, Laura; Bogenrieder, Thomas; de Bono, Johann
errShare
errSave